Cite
MLA Citation
K. Franks et al.. “142P CODAK real-world study: Interim analysis of clinical outcomes in unresectable stage III NSCLC patients treated with durvalumab after chemoradiotherapy (CRT) in the United Kingdom.” Immuno-oncology technology, vol. 16, n.d., p. . http://access.bl.uk/ark:/81055/vdc_100172068669.0x00000a